Molecular basis for sunitinib efficacy and future clinical development.
about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisA Screen of FDA-Approved Drugs for Inhibitors of Zika Virus InfectionNew Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical TrialsNon-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and managementThe treatment landscape in thyroid cancer: a focus on cabozantinibCombining radiotherapy with sunitinib: lessons (to be) learnedTen things you should know about protein kinases: IUPHAR Review 14Anti-angiogenesis and metastasis: a tumour and stromal cell allianceTargeting tumor-associated macrophages to combat pancreatic cancerPazopanib in the treatment of soft tissue sarcomaSynergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazoleEvidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinomaProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibLymphangiogenesis is required for pancreatic islet inflammation and diabetesTumor angiogenesisLenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyPolypharmacology in Precision Oncology: Current Applications and Future ProspectsPhase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorA combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivoDHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFAQuantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.Screening assay for blood vessel maturation inhibitors.Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.Trial watch: Immunostimulatory cytokines in cancer therapy.Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.VEGFR2 translocates to the nucleus to regulate its own transcription.Bacterial proteins and peptides in cancer therapy: today and tomorrowAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Tyrosine kinases in inflammatory dermatologic disease.Response-predictive gene expression profiling of glioma progenitor cells in vitro.
P2860
Q21183974-23DB6D41-7319-409B-92C3-E46FF61F61EBQ24608039-067D0766-77C0-46DF-A1BE-8E92E686B6D6Q26252076-76C31598-0868-43F9-B3D1-0574E2CBD3DEQ26772800-02DBC4C1-DA80-4D23-A0B0-83DC79B97FD1Q26795597-D5625630-8B8A-4C15-BA65-56C867C86FE4Q26796404-F084641F-683A-4F3C-9D3D-2C97D76C52FAQ26800587-32C902E3-440A-4CBB-9206-877239CDFBA0Q26849417-7FD6F678-7D18-4E4B-90B1-A4EFA2BEF650Q26862741-6DD74C2C-58B5-47BA-AC2B-E6196F884FB9Q28076103-6A013B06-7152-4E2E-8522-3EE59E877280Q28269229-74F57D95-A146-4550-A828-572CAC61AF88Q28477256-049E13F9-3E00-4D06-8DE6-B4A87134D26FQ28478709-11E6A524-7054-4A81-A18C-1D9D0C4879B8Q28550556-D70CE833-C3D7-4BB3-B230-4D18C163EB85Q28742322-304CCCBC-896A-4696-BCB1-7E0067002EA0Q29614938-E35C15AB-C3BD-41E5-923D-AA4CF4511612Q30249385-C9BA1D96-3BE7-4173-B70A-E4C03AB2A9B8Q30455612-62E3A768-4197-47C6-8522-5105C014B961Q30846907-8E3C7EA3-9B43-44E5-A85E-9BE0F069B4CFQ33402705-9D43B995-B855-464C-B692-D009957101B9Q33432047-81C979B3-C14B-4AD7-B204-E0CA7CE61520Q33576606-B6846C61-CCB2-44AB-9B71-993AC0B611E0Q33603626-E40643A6-F243-4ED3-894A-A693EC036220Q33624207-98ED3F4C-88F7-40FC-81EC-178C5C2C578DQ33630819-B0A28AE0-E243-4848-AE30-F876BFBBA7A0Q33726782-8E17BD6B-3C05-4C24-B6FB-8F767869FDC7Q33735263-46D6C83B-64DB-4B15-AD1E-8E60325EDBC7Q33801399-42B59715-6F16-4E36-8511-81C2D4B22D0BQ33815701-F07265C0-6C4E-4D6E-83FB-893DF90BA86BQ33840444-DB8DAB13-8266-43AC-9F74-69C0A6DC9B1DQ33862377-5D9B87BC-7CA5-4712-B017-2F0364C602C9Q33871518-AD6A6746-6370-421F-96A4-B4B1CC26FB16Q33877467-10301D7C-C450-47AF-8C93-40E46951335EQ33880165-7FDDF7A2-02E8-45B8-B452-A18D31FC98D8Q34005875-9857FC85-40BC-4201-AD25-122D991177DCQ34043465-588FA22B-13C5-4B62-A440-B6706791799DQ34075830-EF495076-2F50-41F1-B3B1-05085F91CE2EQ34088265-7386199B-2919-48A1-ADFE-4D6E08B47206Q34166503-8354FE17-FBAA-4FEF-901D-1875B1BDA5C6Q34277599-BCEB417A-24E7-420F-AF1B-EE1D163A7FB1
P2860
Molecular basis for sunitinib efficacy and future clinical development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Molecular basis for sunitinib efficacy and future clinical development.
@en
type
label
Molecular basis for sunitinib efficacy and future clinical development.
@en
prefLabel
Molecular basis for sunitinib efficacy and future clinical development.
@en
P2093
P356
P1476
Molecular basis for sunitinib efficacy and future clinical development.
@en
P2093
Eric Raymond
George Demetri
William Sargent
P2888
P304
P356
10.1038/NRD2380
P577
2007-09-01T00:00:00Z